A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: perform (668), apply (638), follow (1000), observe (247), rehearse (2), prepare (1000)

MyelomaCTD21CyclophosphamideDexamethasoneThalidomide(CTD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTD (21)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (21 days) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTD21CyclophosphamideDexamethasoneThalidomideCTDVer1.pdf

Selinexor Bortezomib Dexamethasone

Description
Chemotherapy Protocol Multiple Myeloma Selinexor with Bortezomib and Dexamethasone Regimen • SELINEXOR (PO) – BORTEZOMIB (SC) – DEXAMETHASONE (PO) Indication Selinexor plus bortezomib and
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Selinexor-Bortezomib-Dexamethasone-Ver1.pdf

Institutional information_2024-25

Description
Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application to avoid the same document
Url
/Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2024-25.pdf

Papers Trust Board - 5 November 2024

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 05/11/2024 9:00 - 11:30 The Ark Conference Centre
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-5-November-2024.pdf

Annual-report-2017-18

Description
ANNUAL REPORT AND ACCOUNTS 2017/18 incorporating the quality account 2017/18 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2017-181.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

Papers Trust Board - 13 May 2025

Description
Agenda Trust Board – Open Session Date Time Location Chair Apologies In attendance 13/05/2025 9:00 - 13:00 Conference Room
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-13-May-2025.pdf

Papers Trust Board 27 May 2021

Description
Date Time Location Chair Agenda Trust Board – Open Session 27/05/2021 9:00 - 13:00 Microsoft Teams Peter Hollins 1
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2021-Trust-document/TB-papers/Papers-Trust-Board-27-May-2021.pdf

Papers Trust Board - 11 March 2025

Description
Date Time Location Chair Agenda Trust Board – Open Session 11/03/2025 9:00 - 13:00 Conference Room, Heartbeat Education Centre
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-11-March-2025.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description
Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf
31 to 40 of 609
Previous … 2 3 4 5 6 … Next